Thermo Fisher Scientific Inc (NYSE:TMO) – Research analysts at Jefferies Group lowered their Q1 2018 earnings per share (EPS) estimates for Thermo Fisher Scientific in a note issued to investors on Tuesday. Jefferies Group analyst B. Couillard now anticipates that the medical research company will post earnings of $2.31 per share for the quarter, down from their previous forecast of $2.44. Jefferies Group currently has a “Hold” rating and a $175.00 target price on the stock.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 26th. The medical research company reported $2.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.02 by $0.06. The firm had revenue of $4.77 billion for the quarter, compared to analysts’ expectations of $4.68 billion. Thermo Fisher Scientific had a return on equity of 15.73% and a net margin of 11.58%. The business’s revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 earnings per share.

WARNING: “Equities Analysts Offer Predictions for Thermo Fisher Scientific Inc’s Q1 2018 Earnings (TMO)” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/21/equities-analysts-offer-predictions-for-thermo-fisher-scientific-incs-q1-2018-earnings-tmo.html.

A number of other equities research analysts have also issued reports on TMO. Leerink Swann set a $187.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, April 27th. Barclays PLC set a $175.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 26th. BTIG Research raised their price target on Thermo Fisher Scientific from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Deutsche Bank AG raised their price target on Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Finally, Morgan Stanley raised their price target on Thermo Fisher Scientific from $186.00 to $192.00 and gave the stock an “overweight” rating in a research note on Friday, April 28th. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $187.88.

Shares of Thermo Fisher Scientific (TMO) traded up 0.26% during midday trading on Friday, reaching $182.02. The company had a trading volume of 438,912 shares. The firm’s 50 day moving average price is $176.35 and its 200-day moving average price is $162.18. Thermo Fisher Scientific has a 1-year low of $139.07 and a 1-year high of $182.86. The stock has a market capitalization of $71.21 billion, a price-to-earnings ratio of 33.20 and a beta of 1.06.

A number of hedge funds and other institutional investors have recently made changes to their positions in TMO. Proficio Capital Partners LLC increased its position in shares of Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Cribstone Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after buying an additional 50 shares in the last quarter. Independent Portfolio Consultants Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares in the last quarter. Sharkey Howes & Javer boosted its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares in the last quarter. Finally, CWM LLC boosted its stake in shares of Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 86.93% of the company’s stock.

In related news, insider Thomas W. Loewald sold 1,532 shares of the business’s stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $168.76, for a total transaction of $258,540.32. Following the transaction, the insider now directly owns 41,277 shares in the company, valued at approximately $6,965,906.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the transaction, the chief executive officer now owns 269,279 shares in the company, valued at $46,528,718.41. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,720 shares of company stock worth $4,960,764. 0.49% of the stock is owned by company insiders.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.